

KRAS G13D peptide, 25 mer Biochemical | KRASG13D biochemical

KRAS G13D peptide, 25 mer

CATALOG #
AAA227732


PRODUCT SYNONYMS

KRAS G13D peptide; 25 mer; E3LigaseLigand-LinkerConjugates52; Cereblon Ligand-Linker Conjugates 16; KRASG13D biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	145019-94-9
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	KRAS G13D peptide, 25 mer is encoded by immunomodulatory therapeutic mRNA that can be used to prepare KRAS vaccine[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Thalidomide-O-amido-C3-NH2, CAS 2022182-57-4



Structure
Thalidomide-O-amido-C3-NH2, CAS 2022182-57-4

ADDITIONAL INFORMATION

Related Product Information for KRASG13D biochemical	KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine.
References	1. Lohbeck J, et al. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5260-5262.

NCBI AND UNIPROT INFORMATION

Molecular Weight	388.38
------------------	--------

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://www.aaabiotech.com/krasg13d-biochemical/kras-g13d-peptide-25-mer/227732>